Neuroendocrine tumor (NET) management – the state of the art in 2021, including PRRT

Ali Zarrinpar, MD, Brian Ramnaraign, MD, Steven Hughes, MD, and Kathryn Hitchcock, MD, discuss neuroendocrine tumor (NET) management – the state of the art in 2021, including PRRT.
They give an overview of the current management of neuroendocrine tumors. They describe the use of peptide receptor radionuclide therapy for treatment for NETs and they explain when, in the course of the disease, PRRT is best given